公开(公告)号：DK0556672T3

公开(公告)日：1998-03-02

申请号：DK93101840

申请日：1993-02-05

Applicant: HOECHST AG

Inventor： LINZ WOLFGANG DR ,  SCHOLZ WOLFGANG DR ,  LANG HANS-JOCHEN DR ,  ENGLERT HEINRICH DR ,  ALBUS UDO DR ,  MANIA DIETER DR

IPC: A61K31/155 ,  A61K31/165 ,  A61K31/445 ,  A61P1/16 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P35/00 ,  C07C279/22 ,  C07D213/65 ,  C07D295/14 ,  C07D295/155

Abstract: There are described benzoylguanidines of the formula I in which R(1) or R(2) is an amino group -NR(3)R(4), where R(3) and R(4) are equal to H, (cyclo)alkyl or R(3) is equal to phenyl-(CH2)p- where p = 0, 1, 2, 3 or 4, or phenyl, or R(3) and R(4) together can also be a methylene chain, and in which the other substituent R(1) or R(2) in each case is H, F, Cl, alkyl, alkoxy, CF3, CmF2m+1-CH2-, benzyl or phenoxy, and their pharmaceutically tolerable salts. The compounds according to the invention have very good antiarrhythmic properties, such as they show, for example, in the case of oxygen deficiency symptoms. The compounds are used as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and also for the treatment of angina pectoris, where they preventively inhibit or strongly decrease the pathophysiological processes during the formation of ischaemically induced damage, in particular during the induction of ischaemically induced cardiac arrhythmias.

公开(公告)号：ES2059931T3

公开(公告)日：1994-11-16

申请号：ES90115230

申请日：1990-08-08

Applicant: HOECHST AG

Inventor： LINZ WOLFGANG DR ,  SCHOLKENS BERNWARD PROF DR ,  SCHOLZ WOLFGANG DR ,  WIEMER GABRIELE DR ,  URBACH HANSJORG DR ,  HENNING RAINER DR ,  TEETZ VOLKER DR

IPC: A61K38/55 ,  A61P9/08 ,  A61P9/10 ,  A61P43/00 ,  C07C237/12 ,  C07K5/06 ,  A61K37/64 ,  A61K37/02

Abstract: The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and hyperplasia by administration of angiotensin converting enzyme inhibitors. Administration of compounds of the formula I (I) in which n is 1 or 2, R, R1, R2 and R3 are identical or different and each is hydrogen or an organic radical, and R4 and R5 form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system, is preferred. The invention additionally relates to angiotensin converting enzyme inhibitors and to agents containing these for administration for the treatment of the abovementioned diseases.

公开(公告)号：AT108656T

公开(公告)日：1994-08-15

申请号：AT91119183

申请日：1991-11-11

Applicant: HOECHST AG

Inventor： HEITSCH HOLGER DR ,  HENNING RAINER DR ,  LINZ WOLFGANG DR ,  SCHOELKENS BERNWARD PROF DR ,  URBACH HANSJOERG DR

IPC: A61K31/41 ,  A61K31/415 ,  A61K31/495 ,  A61K31/675 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P43/00 ,  C07D233/64 ,  C07D233/68 ,  C07D233/90 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D403/10

Abstract: The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and/or hyperplasia by administration of angiotensin II receptor blockers, preferably of the imidazole, pyrrole, pyrazole, triazole or tetrazole type.

公开(公告)号：DE59004292D1

公开(公告)日：1994-03-03

申请号：DE59004292

申请日：1990-07-18

Applicant: HOECHST AG

Inventor： KLEEMANN HEINZ-WERNER DR ,  URBACH HANSJOERG DR ,  WAGNER ADALBERT DR ,  RUPPERT DIETER DR ,  LINZ WOLFGANG DR ,  KRAMER WERNER DR DR

IPC: C12N9/99 ,  A61K31/38 ,  A61K31/381 ,  A61K31/415 ,  A61K31/445 ,  A61K31/535 ,  A61K38/55 ,  A61P9/12 ,  C07C237/08 ,  C07C237/22 ,  C07D211/26 ,  C07D211/58 ,  C07D233/54 ,  C07D233/64 ,  C07D295/20 ,  C07D333/24 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  C07D521/00 ,  C07K1/113 ,  C07K5/06 ,  C07K5/065 ,  C07K5/078 ,  C07K14/81 ,  A61K37/64

Abstract: The present invention relates to compounds of the formula I in which A, R , R , R and n are defined as indicated in the description, to processes for the preparation thereof, to the use thereof as medicines and to pharmaceutical compositions containing these.

公开(公告)号：CZ403392A3

公开(公告)日：1993-12-15

申请号：CS403392

申请日：1992-12-31

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH DR ,  MANIA DIETER DR ,  LANG HANS-JOCHEN DR ,  SCHOLZ WOLFGANG DR ,  LINZ WOLFGANG DR ,  ALBUS UDO DR

IPC: A61K31/155 ,  A61K31/165 ,  A61K31/445 ,  A61P1/16 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P35/00 ,  C07C279/22 ,  C07D213/65 ,  C07D295/14 ,  C07D295/155 ,  C07C279/20 ,  C07C277/08 ,  A61K31/40

Abstract: There are described benzoylguanidines of the formula I in which R(1) or R(2) is an amino group -NR(3)R(4), where R(3) and R(4) are equal to H, (cyclo)alkyl or R(3) is equal to phenyl-(CH2)p- where p = 0, 1, 2, 3 or 4, or phenyl, or R(3) and R(4) together can also be a methylene chain, and in which the other substituent R(1) or R(2) in each case is H, F, Cl, alkyl, alkoxy, CF3, CmF2m+1-CH2-, benzyl or phenoxy, and their pharmaceutically tolerable salts. The compounds according to the invention have very good antiarrhythmic properties, such as they show, for example, in the case of oxygen deficiency symptoms. The compounds are used as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and also for the treatment of angina pectoris, where they preventively inhibit or strongly decrease the pathophysiological processes during the formation of ischaemically induced damage, in particular during the induction of ischaemically induced cardiac arrhythmias.

公开(公告)号：CZ431890A3

公开(公告)日：1993-05-12

申请号：CS431890

申请日：1990-09-05

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH CHRISTIAN DR ,  LANG HANS-JOCHEN DR ,  LINZ WOLFGANG DR ,  SCHOLKENS BERNWARD PROF DR ,  SCHOLZ WOLFGANG DR

IPC: C07C279/22 ,  A61K31/155 ,  A61K31/18 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/445 ,  A61K31/455 ,  A61K31/535 ,  A61K31/5375 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  C07C277/00 ,  C07C279/10 ,  C07C311/15 ,  C07C311/47 ,  C07C317/42 ,  C07C317/44 ,  C07C323/60 ,  C07C323/62 ,  C07C323/65 ,  C07C323/67 ,  C07D209/08 ,  C07D211/28 ,  C07D295/14 ,  C07D295/155 ,  C07D295/195 ,  C07D295/22 ,  C07D295/26

Abstract: Benzoylguanidines of the formula I (* CHEMICAL STRUCTURE *) (I) where R(1) or R(2) is equal to R(6)-S(O)n- or R(7)R(8)N-O2S- and the other substituent R(1) or R(2) is in each case equal to H, F, Cl, Br, I, alkyl, alkoxy or phenoxy, R(6)-S(O)n or R(7)R(8)N- and R(6) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, R(7) and R(8) are equal to alkyl or phenylalkyl or phenyl, and in which R(7) and R(8) may also together be a C4-C7 chain, and in which R(7) and R(8), together with the nitrogen atom to which they are bonded, may be a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system, and where R(3), R(4) and R(5) are equal to hydrogen or alkyl, or R(3) and R(4) are together an alkylene chain or R(4) and R(4) are together an alkylene chain, and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmics.

公开(公告)号：CS277644B6

公开(公告)日：1993-03-17

申请号：CS395890

申请日：1990-08-10

Applicant: HOECHST AG

Inventor： LINZ WOLFGANG DR ,  SCHOLKENS BERNWARD PROF DR ,  SCHOLZ WOLFGANG DR ,  WIEMER GABRIELE DR ,  URBACH HANSJORG DR ,  HENNING RAINER DR ,  TEETZ VOLKER DR

IPC: A61K38/55 ,  A61P9/08 ,  A61P9/10 ,  A61P43/00 ,  C07C237/12 ,  C07K5/06 ,  A61K37/02

Abstract: The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and hyperplasia by administration of angiotensin converting enzyme inhibitors. Administration of compounds of the formula I (I) in which n is 1 or 2, R, R1, R2 and R3 are identical or different and each is hydrogen or an organic radical, and R4 and R5 form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system, is preferred. The invention additionally relates to angiotensin converting enzyme inhibitors and to agents containing these for administration for the treatment of the abovementioned diseases.

公开(公告)号：DE4036706A1

公开(公告)日：1992-05-21

申请号：DE4036706

申请日：1990-11-17

Applicant: HOECHST AG

Inventor： HEITSCH HOLGER DR ,  HENNING RAINER DR ,  LINZ WOLFGANG DR ,  SCHOELKENS BERNWARD PROF ,  URBACH HANSJOERG DR

IPC: A61K31/41 ,  A61K31/415 ,  A61K31/495 ,  A61K31/675 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P43/00 ,  C07D233/64 ,  C07D233/68 ,  C07D233/90 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D403/10

Abstract: The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and/or hyperplasia by administration of angiotensin II receptor blockers, preferably of the imidazole, pyrrole, pyrazole, triazole or tetrazole type.

公开(公告)号：CS198090A2

公开(公告)日：1991-08-13

申请号：CS198090

申请日：1990-04-20

Applicant: HOECHST AG

Inventor： WAGNER ADALBERT DR ,  URBACH HANSJORG DR ,  RUPPERT DIETER DR ,  LINZ WOLFGANG DR ,  SCHOLKENS BERNWARD PROF DR

IPC: A61K38/55 ,  A61K38/00 ,  A61P9/00 ,  A61P9/12 ,  C07K1/06 ,  C07K1/113 ,  C07K5/02 ,  C07K5/06 ,  C07K5/065 ,  C07K14/81 ,  C07K5/08

Abstract: The present invention relates to compounds of the formula I in which A and B are, independently of one another, an amino acid, and R , R , R and R are as defined in the description, to processes for the preparation thereof, to their use as medicines and to pharmaceutical agents containing them.

公开(公告)号：DE3926606A1

公开(公告)日：1991-02-14

申请号：DE3926606

申请日：1989-08-11

Applicant: HOECHST AG

Inventor： LINZ WOLFGANG DR ,  SCHOELKENS BERNWARD PROF ,  SCHOLZ WOLFGANG DR ,  WIEMER GABRIELE DR ,  URBACH HANS-JOERG DR ,  HENNING RAINER DR ,  TEETZ VOLKER DR

IPC: A61K38/55 ,  A61P9/08 ,  A61P9/10 ,  A61P43/00 ,  C07C237/12 ,  C07K5/06

Abstract: The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and hyperplasia by administration of angiotensin converting enzyme inhibitors. Administration of compounds of the formula I (I) in which n is 1 or 2, R, R1, R2 and R3 are identical or different and each is hydrogen or an organic radical, and R4 and R5 form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system, is preferred. The invention additionally relates to angiotensin converting enzyme inhibitors and to agents containing these for administration for the treatment of the abovementioned diseases.